Guggenheim Assumes AMAG Pharmaceuticals (AMAG) at Buy; Makena Ascribed Very Little Value

November 7, 2016 6:16 AM EST
Get Alerts AMAG Hot Sheet
Price: $24.20 +0.41%

Rating Summary:
    11 Buy, 10 Hold, 1 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 30 | Down: 30 | New: 23
Trade AMAG Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

Guggenheim assumes coverage on AMAG Pharmaceuticals (NASDAQ: AMAG) with a Buy rating and a price target of $42.00, saying the market is ascribing very little value to Makena.

Analyst Brandon Folkes commented, "At current levels, we believe the market ascribes very little value to Makena (for pre-term birth) post '18. We believe the current share price creates a compelling risk/reward profile, with the potential for significant upside once the Makena generic overhang is removed, and business development further diversifies the company's revenue streams. We model generic erosion on Makena from '18 given the large Medicaid market; however, we believe the Makena franchise will continue to generate meaningful revenues for the company post '18, driven by the Sub-Q."

For an analyst ratings summary and ratings history on AMAG Pharmaceuticals click here. For more ratings news on AMAG Pharmaceuticals click here.

Shares of AMAG Pharmaceuticals closed at $25.20 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, FDA, New Coverage

Related Entities


Add Your Comment